The RAF gene family encodes protein kinases that regulate the MAPK/ERK pathway.
Vemurafenib targets the BRAF V600E mutation in melanoma, improving patient outcomes.
MEK inhibitors can be synergistic with BRAF inhibitors in certain cancers.


